Rice Hall James & Associates’s Madrigal Pharmaceuticals MDGL Stock Holding History

Rice Hall James & Associates’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-843	Closed	-$51K	–	311
2015 Q3	$51K	Sell	843 -38	-4%	-$2.74K	﹤0.01%	299
2015 Q2	$69K	Sell	881 -92	-9%	-$7.72K	﹤0.01%	308
2015 Q1	$66K	Buy	973 +275	+39%	+$23.6K	﹤0.01%	313
2014 Q4	$65K	Sell	698 -232	-25%	-$24K	﹤0.01%	303
2014 Q3	$98K	Buy	930 +11	+1%	+$1.53K	0.01%	295
2014 Q2	$132K	Buy	919 +13	+1%	+$1.9K	0.01%	299
2014 Q1	$137K	Buy	906 +37	+4%	+$7.29K	0.01%	297
2013 Q4	$159K	Buy	+869	New	+$159K	0.01%	296

Other funds holding MDGL

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Rice Hall James & Associates's MDGL Position: Q4 2015 in Review

Rice Hall James & Associates sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2015, closing a stake of 843 shares — an estimated $51K sold.

Rice Hall James & Associates first reported a position in MDGL in Q4 2013 and held it in 8 quarters. The position peaked at $159K in Q4 2013. 75 funds tracked by Wall St. Rank hold MDGL as of Q4 2015.

Rice Hall James & Associates reported no remaining Madrigal Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Rice Hall James & Associates sold 843 Madrigal Pharmaceuticals shares in Q4 2015, an estimated $51K.
Rice Hall James & Associates first reported a position in Madrigal Pharmaceuticals in Q4 2013 and held it in 8 quarters.
Rice Hall James & Associates's Madrigal Pharmaceuticals position peaked at $159K in Q4 2013.
75 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2015.

Based on Rice Hall James & Associates's 13F filing for Q4 2015, filed 28 Jan 2016.